Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): Response to escitalopram treatment and basal serotonin transporter (SERT) density

Behavioural Brain Research

Volumn 256, Issue , 2013, Pages 545-553

  Wolmarans, De Wet ^a   Brand, Linda ^a   Stein, Dan J ^b   Harvey, Brian H ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Deer mouse; Escitalopram; Frontal cortex striatum; Obsessive compulsive disorder (OCD); Serotonin transporter (SERT); Stereotypy

Indexed keywords

ESCITALOPRAM; SEROTONIN TRANSPORTER;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; DRUG MEGADOSE; FRONTAL CORTEX; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PEROMYSCUS; PRIORITY JOURNAL; PROTEIN BINDING; STEREOTYPY; STRIATE CORTEX; TREATMENT RESPONSE; VALIDATION PROCESS;

5HT; CAGE REVOLUTIONS (INDICATION OF PATTERN RUNNING ACTIVITY); CR; DA; DEER MOUSE; DOPAMINE; ESCITALOPRAM; FRONTAL CORTEX-STRIATUM; HIGH-STEREOTYPICAL; HS; NON- AND LOW-STEREOTYPICAL; OBSESSIVE-COMPULSIVE; OBSESSIVE-COMPULSIVE DISORDER; OBSESSIVE-COMPULSIVE DISORDER (OCD); OC; OCD; SELECTIVE SEROTONIN REUPTAKE INHIBITOR; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN TRANSPORTER (SERT); SERT; SSRI; STEREOTYPY; VBI; VERTICAL BEAM INTERRUPTIONS (INDICATION OF JUMPING ACTIVITY); [NS/LS];

ANIMALS; BRAIN; CITALOPRAM; DISEASE MODELS, ANIMAL; OBSESSIVE-COMPULSIVE DISORDER; PEROMYSCUS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STEREOTYPED BEHAVIOR;

EID: 84884577396     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.08.049     Document Type: Article

References (53)

1. Güldenpfennig M., Wolmarans D.W., du Preez J.L., Stein D.J., Harvey B.H. Cortico-striatal oxidative status, dopamine turnover and relation with stereotypy in the deer mouse. Physiol Behav 2011, 103:404-411. 10.1016/j.physbeh.2011.03.008.
2. Korff S., Stein D.J., Harvey B.H. Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 2008, 32:348-355.
3. Korff S., Stein D.J., Harvey B.H. Cortico-striatal cyclic AMP-phosphodiesterase-4 signalling and stereotypy in the deer mouse: attenuation after chronic fluoxetine treatment. Pharmacol Biochem Behav 2009, 92:514-520. 10.1016/j.pbb.2009.01.025.
4. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington, 943 pp. 4th ed.
5. Abramowitz J.S., Wheaton M.G., Storch E.A. The status of hoarding as a symptom of obsessive-compulsive disorder. Behav Res Ther 2008, 46:1026-1033. 10.1016/j.brat.2008.05.006.
6. Bartz J.A., Hollander E. Is obsessive-compulsive disorder an anxiety disorder?. Prog Neuro-Psychopharmacol Biol Psychiatry 2006, 30:338-352. 10.1016/j.pnpbp.2005.11.003.
7. Fineberg N.A., Craig K.J. Pharmacological treatment for obsessive-compulsive disorder. Psychiatry 2007, 6:234-239. 10.1016/j.mppsy.2007.04.001.
8. El Mansari M., Blier P. Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 2006, 30:362-373. 10.1016/j.pnpbp.2005.11.005.
9. Nestadt G., Samuels J., Riddle M.A., Liang K-, Bienvenu O.J., Hoehn-Saric R., et al. The relationship between obsessive-compulsive disorder and anxiety and affective disorders: results from the Johns Hopkins OCD family study. Psychol Med 2001, 31:481-487.
10. Vythilingum B., Cartwright C., Hollander E. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 2000, 15:S7-S13.
11. Markarian Y., Larson M.J., Aldea M.A., Baldwin S.A., Good D., Berkeljon A., et al. Multiple pathways to functional impairment in obsessive-compulsive disorder. Clin Psychol Rev 2010, 30:78-88. 10.1016/j.cpr.2009.09.005.
12. Maia T.V., Cooney R.E., Peterson B.S. The neural bases of obsessive - compulsive disorder in children and adults. Dev Psychopathol 2008, 20:1251-1283.
13. Atmaca M., Onalan E., Yildirim H., Yuce H., Koc M., Korkmaz S., et al. Serotonin transporter gene polymorphism implicates reduced orbito-frontal cortex in obsessive-compulsive disorder. J Anxiety Disord 2011, 25:680-685. 10.1016/j.janxdis.2011.03.002.
14. Matsumoto R., Ichise M., Ito H., Ando T., Takahashi H., Ikoma Y., et al. Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11C]DASB PET study. Neuroimage 2010, 49:121-126. 10.1016/j.neuroimage.2009.07.069.
15. Hesse S., Müller U., Lincke T., Barthel H., Villmann T., Angermeyer M.C., et al. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res - Neuroimaging 2005, 140:63-72.
16. Reimold M., Smolka M.N., Zimmer A., Batra A., Knobel A., Solbach C., et al. Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - A [11C]DASB PET study. J Neural Transm 2007, 114:1603-1609.
17. Zitterl W., Aigner M., Stompe T., Zitterl-Eglseer K., Gutierrez-Lobos K., Wenzel T., et al. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacology 2008, 33:3126-3134.
18. Langen M., Kas M.J.H., Staal W.G., van Engeland H., Durston S. The neurobiology of repetitive behavior: of mice. . .. Neurosci Biobehav Rev 2011, 35:345-355.
19. Rasmussen S.A., Eisen J.L., McElroy J., Pigott D., Shahady G. The epidemiology and differential diagnosis of obsessive compulsive disorder. J Clin Psychiatry 1994, 55:5-14.
20. Geyer M.A., Markou A. Animal models of psychiatric disorders psychopharmacology fourth generation of progress 2000, 13/08/2013.
21. Joel D. Current animal models of obsessive compulsive disorder: a critical review. Prog Neuro-Psychopharmacol Biol Psychiatry 2006, 30:374-388. 10.1016/j.pnpbp.2005.11.006.
22. Korff S., Harvey B.H. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology. Psychiatr Clin North Am 2006, 29:371-390. 10.1016/j.psc.2006.02.007.
23. Overall K.L. Natural animal models of human psychiatric conditions: assessment of mechanism and validity. Prog Neuro-Psychopharmacol Biol Psychiatry 2000, 24:727-776. doi: http://dx.doi.org.nwulib.nwu.ac.za/10.1016/S0278-5846(00)00104-4.
24. Greene-Schloesser D.M., Van der Zee E.A., Sheppard D.K., Castillo M.R., Gregg K.A., Burrow T., et al. Predictive validity of a non-induced mouse model of compulsive-like behavior. Behav Brain Res 2011, 221:55-62.
25. Wang L., Simpson H.B., Dulawa S.C. Assessing the validity of current mouse genetic models of obsessive-compulsive disorder. Behav Pharmacol 2009, 20:119-133.
26. Fineberg N.A., Potenza M.N., Chamberlain S.R., Berlin H.A., Menzies L., Bechara A., et al. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology 2010, 35:591-604.
27. Albelda N., Joel D. Current animal models of obsessive compulsive disorder: an update. Neuroscience 2012, 211:83-106. 10.1016/j.neuroscience.2011.08.070.
28. Hadley C., Hadley B., Ephraim S., Yang M., Lewis M.H. Spontaneous stereotypy and environmental enrichment in deer mice (Peromyscus maniculatus): reversibility of experience. Appl Anim Behav Sci 2006, 97:312-322. 10.1016/j.applanim.2005.08.006.
29. Bergqvist P.B., Bouchard C., Blier P. Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder. Biol Psychiatry 1999, 45:164-174.
30. Joel D.J., Stein D., Schreiber R. Animal models of obsessive-compulsive disorder: from bench to bedside via endophenotypes and biomarkers. Animal and translational models for CNS drug discovery 2008, 133-164. Academic Press, San Diego. R.A. McArthur, F. Borsini (Eds.).
31. Overduin M.K., Furnham A. Assessing obsessive-compulsive disorder (OCD): a review of self-report measures. J Obsessive-Compulsive Relat Disord 2012, 1:312-324.
32. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Delgado P., Heninger G.R., et al. The Yale-brown obsessive compulsive scale. II. Validity. Arch Gen Psychiatry 1989, 46:1012-1016.
33. Storch E.A., Bagner D., Merlo L.J., Shapira N.A., Geffken G.R., Murphy T.K., et al. Florida obsessive-compulsive inventory: development, reliability, and validity. J Clin Psychol 2007, 63:851-859.
34. Abramowitz J.S., Deacon B.J., Olatunji B.O., Wheaton M.G., Berman N.C., Losardo D., et al. Assessment of obsessive-compulsive symptom dimensions: development and evaluation of the dimensional obsessive-compulsive scale. Psychol Assess 2010, 22:180-198.
35. Clark D.A., Beck A.T., Antony M.M., Swinson R.P., Steer R.A. Screening for obsessive and compulsive symptoms: validation of the Clark-Beck obsessive-compulsive inventory. Psychol Assess 2005, 17:132-143.
36. Powell S.B., Newman H.A., Pendergast J.F., Lewis M.H. A rodent model of spontaneous stereotypy: initial characterization of developmental, environmental, and neurobiological factors. Physiol Behav 1999, 66:355-363. 10.1016/S0031-9384(98)00303-5.
37. Owens M.J., Knight D.L., Nemeroff C.B. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001, 50:345-350.
38. Aschhoff S., Schroff K-, Wildenauer D.B., Richter E. Nicotine consumption of several mouse strains using a two bottle choice paradigm. J Exp Anim Sci 2000, 40:171-177.
39. Presti M.F., Lewis M.H. Striatal opioid peptide content in an animal model of spontaneous stereotypic behavior. Behav Brain Res 2005, 157:363-368.
40. Presti M.F., Watson C.J., Kennedy R.T., Yang M., Lewis M.H. Behavior-related alterations of striatal neurochemistry in a mouse model of stereotyped movement disorder. Pharmacol Biochem Behav 2004, 77:501-507.
41. Sato H., Skelin I., Diksic M. Chronic buspirone treatment decreases 5-HT1B receptor densities and the serotonin transporter but increases the density of 5-HT2A receptors in the bulbectomized rat model of depression: an autoradiographic study. Brain Res 2010, 1345:28-44. 10.1016/j.brainres.2010.05.054.
42. Jenike M.A. Obsessive-compulsive disorder: efficacy of specific treatments as assessed by controlled trials. Psychopharmacol Bull 1993, 29:487-498.
43. Fineberg N.A., Nigam A., Sivakumaran T. Pharmacologic strategies for treatment-resistant OCD: a review of the evidence. Psychiatric Ann 2006, 36:464-473.
44. Nakajima S., Suzuki T., Watanabe K., Kashima H., Uchida H. Accelerating response to antidepressant treatment in depression: a review and clinical suggestions. Prog Neuro-Psychopharmacol Biol Psychiatry 2010, 34:259-264. 10.1016/j.pnpbp.2009.12.001.
45. Saxena S., Rauch S.L. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am 2000, 23:563-586. 10.1016/S0193-953X(05)70181-7.
46. Daw N.D., Kakade S., Dayan P. Opponent interactions between serotonin and dopamine. Neural Netw 2002, 15:603-616. 10.1016/S0893-6080(02)00052-7.
47. Fletcher P.J., Korth K.M., Chambers J.W. Selective destruction of brain serotonin neurons by 5,7-dihydroxytryptamine increases responding for a conditioned reward. Psychopharmacology (Berl) 1999, 147:291-299.
48. Cools R., Roberts A.C., Robbins T.W. Serotoninergic regulation of emotional and behavioural control processes. Trends Cogn Sci (Regul Ed) 2008, 12:31-40.
49. Vermeire S., Audenaert K., De Meester R., Vandermeulen E., Waelbers T., De Spiegeleer B., et al. Serotonin 2A receptor, serotonin transporter and dopamine transporter alterations in dogs with compulsive behaviour as a promising model for human obsessive-compulsive disorder. Psychiatry Res: Neuroimaging 2012, 201:78-87. 10.1016/j.pscychresns.2011.06.006.
50. Shanahan N.A., Velez L.P., Masten V.L., Dulawa S.C. Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice. Biol Psychiatry 2011, 70:1039-1048.
51. Tucci M.C., Dvorkin-Gheva A., Graham D., Amodeo S., Cheon P., Kirk A., et al. Effects of the serotonergic agonist mCPP on male rats in the quinpirole sensitization model of obsessive-compulsive disorder (OCD). Psychopharmacology (Berl) 2013, 227:277-285.
52. Tsaltas E., Kontis D., Chrysikakou S., Giannou H., Biba A., Pallidi S., et al. Reinforced spatial alternation as an animal model of obsessive-compulsive disorder (OCD): investigation of 5-HT2C and 5-HT1D receptor involvement in OCD pathophysiology. Biol Psychiatry 2005, 57:1176-1185. 10.1016/j.biopsych.2005.02.020.
53. Kontis D., Boulougouris V., Papakosta V.M., Kalogerakou S., Papadopoulos S., Poulopoulou C., et al. Dopaminergic and serotonergic modulation of persistent behaviour in the reinforced spatial alternation model of obsessive-compulsive disorder. Psychopharmacology (Berl) 2008, 200:597-610. doi:10.1007/s00213-008-1241-5; 10.1007/s00213-008-1241-5.